Janssen Sciences Ireland Uc

This study provides continued access to the HIV medication rilpivirine for children who previously took it in earlier trials and are benefiting from it. Researchers will monitor 48 children with HIV-1 for up to 4 years to track long-term safety while they continue taking the medi…

This trial provides continued access to the HIV medication etravirine for children (aged 2+) and adults who successfully completed a previous study with the drug and are still benefiting from it. The goal is to supply the medication until participants can switch to a commercially…